Werewolf Therapeutics, Inc.
HOWL
$2.05
$0.136.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -92.95% | -90.55% | -86.84% | -62.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -92.95% | -90.55% | -86.84% | -62.57% |
| Cost of Revenue | 22.63% | -1.21% | -1.20% | -27.32% | -34.30% |
| Gross Profit | -74.69% | -63.50% | -92.78% | -51.38% | 3.31% |
| SG&A Expenses | -0.30% | 6.21% | 11.67% | 11.79% | 9.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.97% | 22.55% | 24.87% | 4.74% | -1.73% |
| Operating Income | -25.15% | -63.78% | -81.70% | -62.59% | -32.56% |
| Income Before Tax | -36.13% | -74.15% | -88.70% | -66.56% | -31.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.13% | -74.15% | -88.70% | -66.56% | -31.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.13% | -74.15% | -88.70% | -66.56% | -31.20% |
| EBIT | -25.15% | -63.78% | -81.70% | -62.59% | -32.56% |
| EBITDA | -26.13% | -66.47% | -85.29% | -65.07% | -33.51% |
| EPS Basic | -22.09% | -50.02% | -55.05% | -34.88% | -5.38% |
| Normalized Basic EPS | -23.27% | -48.89% | -53.86% | -33.75% | -4.38% |
| EPS Diluted | -19.52% | -52.68% | -57.83% | -37.51% | -7.66% |
| Normalized Diluted EPS | -23.70% | -48.47% | -53.42% | -33.33% | -4.02% |
| Average Basic Shares Outstanding | 13.12% | 18.17% | 21.57% | 20.97% | 20.26% |
| Average Diluted Shares Outstanding | 12.74% | 18.52% | 21.93% | 21.35% | 20.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |